Safety, Tolerability and Pharmacokinetics of Increasing Doses of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients

NCT02265679 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis

Interventions

DRUG: BIIL 284 BS, low dose, pediatric patients
DRUG: BIIL 284 BS, medium dose, pediatric patients
DRUG: BIIL 284 BS, high dose, pediatric patients
DRUG: BIIL 284 BS, low dose, adult patients
DRUG: BIIL 284 BS, medium dose, adult patients
DRUG: BIIL 284 BS, high dose, adult patients
DRUG: Placebo

Sponsor

Boehringer Ingelheim